Hydromorphone controlled release - DURECT Corporation

Drug Profile

Hydromorphone controlled release - DURECT Corporation

Alternative Names: ORADUR-Hydromorphone; PTI 202

Latest Information Update: 13 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator DURECT Corporation
  • Developer Pain Therapeutics
  • Class Morphine derivatives; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Pain

Most Recent Events

  • 13 Jul 2017 Hydromorphone controlled release is still in phase I trials for Pain in USA (DURECT Corporation pipeline, July 2017)
  • 01 Dec 2016 Pain Therapeutics returns development and commercialisation rights for Hydromorphone controlled release to DURECT Corporation
  • 07 Aug 2014 Phase-I clinical trials in Pain (Abuse-resistant) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top